Exelixis announces results from randomized phase 2 trial CABOSUN
Exelixis announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma . The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS. May 23, 2016